{
    "clinical_study": {
        "@rank": "47117", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive\n      adults. T-20 is an anti-HIV drug."
        }, 
        "brief_title": "A Study of T-20 in HIV-Positive Adults", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by\n      subcutaneous infusion and 2 by subcutaneous injection.  The entire study lasts 7 weeks;\n      including a 2-week screening period, followed by 28 days of treatment and 1 week of\n      follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the\n             screening visit.\n\n          -  Antibiotics for bacterial infections.\n\n          -  Prophylactic medications for P. carinii pneumonia and for M. avium, including\n             azithromycin.\n\n          -  Medications for symptomatic treatment such as antipyretics, analgesics, and\n             antiemetics.\n\n        Patients must have:\n\n        HIV-1 seropositive status.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n        Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the\n        cervix, and non-disseminated stable Kaposi's sarcoma).\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Patients must not be taking any concurrent antiretroviral therapy (for at least 2\n             weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen\n             which has not changed for at least 6 weeks prior to baseline.\n\n          -  Treatment with any of the following:\n\n          -  immunomodulators, biological response modifiers, chemotherapy that cannot be\n             discontinued for the duration of the study, astemizole, terfenadine, cisapride,\n             triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30\n             days prior to the initial visit.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Evidence of active opportunistic infections, or unexplained temperature greater than\n             or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening\n             visit.\n\n          -  Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for\n             15 days) within 30 days prior to screening visit.\n\n          -  Diagnosis of hemophilia or other clotting disorders.\n\n        Prior Medication:\n\n        Excluded:\n\n        - Prior treatment with an HIV vaccine.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Major organ allograft.\n\n        Risk Behavior:\n\n        Excluded:\n\n        Evidence of substance abuse or addiction that, in the opinion of the investigator, may\n        interfere with the patient's ability to comply with the dosing schedule and protocol\n        evaluations."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "78", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002228", 
            "org_study_id": "295A", 
            "secondary_id": "TRI-003"
        }, 
        "intervention": {
            "intervention_name": "Enfuvirtide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Enfuvirtide"
        }, 
        "keyword": [
            "Injections, Subcutaneous", 
            "HIV-1", 
            "Anti-HIV Agents", 
            "peptide T20"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Univ of Alabama at Birmingham / 1917 AIDS O/P Cln"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "900951793"
                    }, 
                    "name": "UCLA School of Medicine / Ctr for Research and Education"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Quest Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altamonte Springs", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32701"
                    }, 
                    "name": "IDC Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ / Infect Dis Div / Pasavant Pav 828"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookline", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02445"
                    }, 
                    "name": "CRI of New England"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Med Ctr / C & D Building"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ North Carolina at Chapel Hill / Dept of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Univ of Texas / Thomas Street Clinic"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Evaluation of the Safety, Plasma Pharmacokinetics, and Antiviral Activity of T-20 Administered to HIV-1 Positive Adults By Continuous Subcutaneous Infusion or Subcutaneous Injection", 
        "overall_official": {
            "last_name": "Sam Hopkins", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002228"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Trimeris", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1999"
    }, 
    "geocoordinates": {
        "CRI of New England": "42.332 -71.121", 
        "IDC Research Initiative": "28.661 -81.366", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "NYU Med Ctr / C & D Building": "40.714 -74.006", 
        "Northwestern Univ / Infect Dis Div / Pasavant Pav 828": "41.878 -87.63", 
        "Quest Clinical Research": "37.775 -122.419", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "UCLA School of Medicine / Ctr for Research and Education": "34.052 -118.244", 
        "Univ North Carolina at Chapel Hill / Dept of Medicine": "35.913 -79.056", 
        "Univ of Alabama at Birmingham / 1917 AIDS O/P Cln": "33.521 -86.802", 
        "Univ of Texas / Thomas Street Clinic": "29.76 -95.369"
    }
}